The liposomal delivery method enhances absorption and bioavailability
PMCID: PMC4094061
The formula is enriched with biotin, vitamin C, hyaluronic acid, and alpha lipoic acid to complement collagen intake
(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)
This systemic mechanism is part of why TB-500 is sometimes considered for injuries that involve more diffuse tissue involvement or chronic, widespread inflammation rather than a single discrete injury site
After TMB substrate solution is added, only those wells that contain Human PRL, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color
